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Threonine and tyrosine residue phosphorylation of a 42 kDa protein identified as mitogen-activated protein kinase (MAP kinass) was stimulated 
in extracts from TPA-pretreated cells. It is further shown that TPA pretreatment leads to the enhancement of an activity that will induce reactivation 
of dephosphorylated/inactivated MAP kinase. This TPA-induced activity inducts the threonine and tyrosine phosphorylation of p42 in extracts 
from unstimulated cells. 
MAP kinase; Protein kinase C; Phorbol ester 
1. INTRODUCTION 2. MATERIALS AND METI-IODS 
Phorbol esters stimulate a variety of responses in cul- 
tured cells including mitogenesis and differentiation (re- 
viewed in [l]). This broad spectrum of events has been 
attributed to the activation of members of the protein 
kinase C (PKC) family (reviewed in [2,3]), which appear 
to function as high affinity receptors for biologically 
active phorbol esters (see [4]). Whether individual PKC 
isoforms are responsible for particular elements of these 
complex responses remains a critical issue. The lack of 
understanding with respect to the function of individual 
PKC isoforms in vivo is largely due to the limited infor- 
mation available on the specificity of these enzymes and 
to the dearth of physiological substrates of known func- 
tion. As a prelude to defining PKC substrates, we have 
investigated the TPA-induced tyrosineithreonine phos- 
phorylation of a 42 kDa protein [5-71 in the U937 cell 
line. These human monocytic cells express a number of 
PKC isoforms (a, p, E, c; D.K. Ways, personal corn- 
munication) and as such provide a useful model system 
for an analysis of isoform specificity. We report here 
that acute TPA treatment of U937 cells stimulates an 
activity that induces the tyrosine and threonine phos- 
phorylation of the 42 1cDa MAP kinase. 
ADbreviu/ions: MAP-2, microtubule-associated protein 2; MAP ki- 
nase, mitogen-activated kinase; MBP, myelin basic protein; PBS, 
phosphate-buffered saline; PKC, protein kinase C; PP2A, protein 
phosphatase 2A; TPA, tetradecanoyl phorbol acetate. 
Correspotrdence addtxw: P.J. Parker, Protein Phosphorylation Labo- 
ratory, Imperial Cancer Research Fund, 44 Lincoln’s Inn Fields, Lon- 
don WC2A 3PX, UK. Fax: (44) (71) 405 0190. 
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2.1. Materiab 
Radioisotopes and the ECL Western blotting kit were obtained 
from Amersham, UK. Other chemicals and biochemicals were ob- 
tained from Sigma, UK. Microtubulc-associated protein 2 (MAP2) 
was purified according to [8,9]. Protein phosphatase 2A (PPZA) was 
purified according to Ramachandran et al. [IO]; PP2A was also gene- 
rously provided by Professor P. Cohen, Dundee. 
2.2. Ccl! culrure and treatment 
U937 cells were grown in RPM1 1640 medium containing 5% fetal 
calf serum in 5% CO,. Subconfluent cells were harvested at a density 
between 0.5 and 1 .O x 1 06/ml. Cells were washed once in phosphate- 
buffered saline (PBS) and resuspended in PBS at a density of 18.8 x 
lO~/ml. Cells were treated with 160 nM TPA (or the ethanol vehicle) 
for 8 min at 30°C; this time and dose of TPA were determined to be 
optimum for the subsequent in vitro phosphorylation of p42 (see 
below). The cells were then pelleted in a microcentrifuge, the superna- 
tant discarded and the cell pellet frozen in liquid nitrogen. 
2.3. In vitro phosplrorylatiotr of ~42 
Frozen cell pcllcts wcrc extracted in extraction buffer (EB; 20 mM 
P-glycerophosphate (pH 7.5), 20 mM NaF, 2 mM EDTA, 0.2 mM 
Na,VO,, 10 mM benzamidine, 25 @ml leupeptin, 50 ,@ml PMSF, 
0.3% v/v @mercaptoethanol) using 1 ml/lOy cells. Protein concentra- 
tion was IO-15 mg/ml. Crude extracts were centrifuged at 12 000 rpm 
for 8 min at 4°C in a microcentrifuge. 
The soluble fraction was incubated for 7 min at 30°C in 20 mM 
P-glycerophosphate (pH 7.5), 0.2 mM NalVO,, 10 mM MgCl,, 0.13 
mM [y-“2P]ATP (500 counts/pmol) at a protein concentration of 1.3- 
1.9 mg/ml. Reactions were stopped by addition of SDS sample buffer 
or by dilution (see below). Proteins were separated on 10% SDS 
polyacrylamide gels and radiolabelled proteins detected by autoradio- 
graphy. The effects of incubation in vitro were time-dependent and 7 
min proved to be optimum for these conditions (not shown). 
2.4. MAP kinase assays 
MAP kinase activity was assayed by incubation of the crude soluble 
fraction or column fractions in 20 mM fi-glycerophosphate, 20 mM 
NaF, 2 mM EDTA, 0.2 mM Na3VOq, 10 mM MgCl,, 0.13 mM 
[P~~P]ATP (1000 counts/pmol), 0.28 m&ml myelin basic protein 
(MBP) or 0.56 mg/ml MAP-2 as indicated for 10 min at 30°C. Reac- 
tions were stopped by spotting 30 fll (out of a total volume of 45 ~1) 
onto 3MM paper which was dropped into 20% TCA. Papers were 
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washed 3 x 10 min in 20% TCA and then counted by Cerenkov. A 
unit of MAP kinase activity is defined as that which incorporates 1 
nmol/min into substrate under these standard assay conditions. 
2.5. Phemyl-Sepharose chromctrography 
Ccl1 pellets were extracted in EB and the soluble fraction incubated 
with M@ATP as described above. The reactions were stopped by 
dilution 1: 1 with ice-cold El3 containing 0.2 M NaCl, and loaded onto 
a phenyl-Sepharose at a flow rate of 0.4 mllmin. Up to 10 mg of 
protein was loaded onto a 1 ml column. The column was washed with 
10 ml of EB containing 0.1 M NaCl followed by 10 ml of EB. MAP 
kinase was step-eluted with EB containing 50% ethanediol at a. flow 
rate of 0.04 ml/min. 
2.6. Mono Q and Mono S chromafogruphy 
Cell pellets were extracted in EB as described. The soluble fraction 
(20 mg) was loaded onto a 1 ml Mono Q (5/5) column, equilibrated 
in El3. The column was washed with 5 ml of EB and developed with 
a linear 5 ml gradient from O-l.0 M NaCI. In some experiments the 
peak fractions of MAP kinase reactivating activity (see results) were 
pooled and loaded onto a Mono S (S/5) column. The column was 
washed and developed in the same way as the Mono Q column. 
2.1. MAP kincrse ittcrctivctrion 
100-200~1 of MAP kinasc, eluted off the phcnyl-Sepharosecolumn, 
was dialysed in 2 x 1 litre of TE (20 mM Tris-MCI (PI-I 7.5). 2 mM 
EDTA, 10 mM benzamidine, 50 puglml PMSF, 0.3% B-mercaptoetha- 
no]) for 4.5 h at 4°C. After dialysis, leupeptin was added to a final 
concentration of 25 @nl. Dialysed MAP kinase was incubated for 
20 min at 30°C with PP2A (10 U/ml) in 20 mM Tris-I-ICI (pW 7.5). 
2 mM EDTA, 10 mM benzamidine, 25 ,@ml leupeptin, 50 &ml 
PMSF. 0.08 mM DTT, 0.25 mM/?-mercaptoethanol, 0.17 mg/ml BSA. 
PPZA was added as a 60 U/ml stock in 20 mM Tris-HCI (PI-I 7.5), I 
mdml BSA, 0.5 mM DTT. The inactivation was stopped by addition 
of 20 mM NaF, 2 mM EDTA (pH 7.0). Inactivation was time- 
dependent and this routine 2Omin treatment resulted in -70% inactiva- 
tion of MAP kinasc. 
2.8. MAP kitrave rectctivcrrion 
Fractions derived from Mono Q or Mono S column fractionation 
were incubated in the presence or absence of PPZA-inactivated MAP 
kinase. Inactivated MAP kinase (as indicated in the text or figure 
legend) was added with column fractions to tubes, which also con- 
tained 20 mM /3-glycerophosphate (pH 7.S), 20 mM NaF, 2 mM 
EDTA, 0.2 mM Na,VO,, 10 mM MgCI,. 0.13 mM [y-“*P]ATP (1000 
counts/ pmol) and 0.22 mg/ml MBP in a final volume of45@. Incuba- 
tions were carried out for 10 min and the phosphorylation of the MBP 
determined as above. A unit of MAP kinase activator is defined as that 
increasing the MAP kinase activity by one unit under the conditions 
described. 
2.9. Other methods 
Protein concentration was determined by the method of Bradford 
[I I]. Phospho-amino acid analysis was carried out following transfer 
of proteins to PVDF membranes as described previously [12]. Antisera 
were raised to the peptide ITVEEALAHPYLEQYYDPTFDEPV 
(based on the ERK-I sequence; [13,14] coupled to keyhole limpet 
hemocyanin. Western analyses were carried out using an ECL kit 
according to the manufacturer’s recommendation at a serum dilution 
of l/5000. 
3. RESULTS 
In order to determine whether the kinase(s) responsi- 
ble for p42 phosphorylation was stable to extraction, 
U937 cells with or without a TPA pretreatment were 
lysed in buffers designed to inhibit serine/threonine and 
(Fig. I conrittrced on the nesf page 4) 
tyrosine phosphatases; extracts were subsequently incu- 
bated in vitro with Mg’*-ATP. Fig. la shows that ex- 
tracts from TPA-pretreated cells retain kinase activity 
that leads to the phosphorylation of ~$2; very little 
activity is detected in control extracts. Phospho-amino 
acid analysis indicates that both tyrosine and threonine 
residues of p42 become phosphorylated in TPA-treated 
extracts (Fig. 1 b). The rate of dephosphorylation of 
“‘P-labelled ~$2 added to extracts from control or TPA- 
treated cells is indistinguishable (not shown). This indi- 
cates that TPA treatment leads to enhanced kinase ac- 
tivity and not decreased phosphatase activity. 
In view of the apparent molecular weight and 
phospho-amino acid content of ~42, the relationship 
between this protein and the mitogen-activated kinase 
(MAP kinase; [G, 15,161) was investigated. Chromatog- 
raphy of the phosphorylated extract on phenyl-Sepha- 
rose showed that the 32P-labelled p42 and kinase activity 
co-eluted in the 50% ethanediol eluate (Fig. 2a and b). 
This kinase activity phosphorylated both MAP-2 (Fig. 
2b) and myelin basic protein (MBP: not shown) consis- 
tent with the specificity of MAP kinase [17]. No 32P- 
labelled p42 was obtained from fractionated control 
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Fig. 1. Phosphorylation of ~42 in vitro, (a) Extracts from control (-) 
or TPA- (+) treated cells were incubated as described in section 2. 
Labelled proteins were separated by SDS-PAGE and visualised by 
autoradiography. The arrow indicates the phosphorylated ~42 pro- 
tein. The arrowheads represent molecular weight markers which are 
in descending order: phosphorylase (92 kDa), bovine serum albumin 
(66.5 kDa) and ovalbumin (45 kDa). (b) The 32P-lnbelled p42 protein 
derived from TPA treated cells (as in (a)) and an equivalent gel piece 
from a control sample were extracted, hydrolysed and analysed for 
phospho-amino acid content. Internal unlabelled standards were in- 
cluded to allow identification: Pi, inorganic phosphate; PS, phospho- 
serine; PT, phosphothreonine; PY, phosphotyrosine; 0, origin. 
extracts and similarly negligible kinase activity was elut- 
ed from the phenyl-Sepharose column (Fig. 2b). A fur- 
ther indication that ~42 is the human equivalent of 
MAP kinase is provided by the observation that anti- 
sera raised to a synthetic peptide based on the published 
ERK- 1 sequence [13,14] specifically recognises a 42 
kDa polypeptide eluting with the p42/MAP kinase ac- 
tivity of both phenyl-Sepharose and Mono Q columns 
(not shown). Thus it appears that p42 is indeed a form 
of MAP kinase and it is subsequently referred to as 
such. 
As observed previously for purified MAP kinase [ 161, 
treatment of the phenyl-Sepharose eluate from the 
(Fig. 2 continued on the next page) 
TPA-treated U937 cells with PP2A inactivates the ki- 
nase; this parallels loss of [32P]phosphate derived from 
in vitro labelling (data not shown). Since the extraction 
procedure employed here allows the retention in vitro 
of both tyrosine and threonine phosphorylating activ- 
ity, the PP2A-inactivated MAP kinase was used to 
screen for a reactivating activity. Such an activity was 
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Fig. 2. Co-elution of p42 and MAP kinase on phenyl-Sepharose chro- 
matrography. (a) Phosphorylated extracts from control (upper panel) 
and TPA treated (lower panel) cells were chromatographed on phenyl- 
Sepharose as described in section 2. Samples from eluted fractions (as 
indicated) were analysed by SDS-PAGE for J2P-labelled p42 content 
(arrow in lower panel). Arrowheads indicate molecular weight mar- 
kers as in Fig. I. (b) Phosphorylated extracts derived from control 
(0-o) or TPA treated cells (*a) were chromatographed on phenyl- 
Sepharose and analysed for MAP kinasc activity (upper panel) and for 
‘2P-labelled p42 content by SDS-PAGE, autoradiography and densi- 
tometry (lower panel). 
detected in the initial gradient fractions from an extract 
separated on a Mono Q column (Fig. 3a). Consistent 
with the phosphorylation of p42 found in cell extracts 
(see Fig. 1) this MAP kinase activator was increased by 
TPA treatment of cells. The p42lMAP kinase itself 
elutes at a higher NaCl concentration and is largely 
separated from the MAP kinase activator. 
In order to further fractionate and characterize the 
MAP kinase activator, peak fractions from a Mono Q 
column were applied to a Mono S column and the activ- 
ity eluted with a NaCl gradient. With this relatively 
steep gradient the MAP kinase activator was found to 
elute at -450 m&I NaCl (Fig. 3b). 
To assess the relationship between the MAP kinase 
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(Fig. 3 contimed on she m.xt purge) 
activator and the extract threonine/tyrosine kinase ac- 
tivities stimulated by TPA treatment, the partially puri- 
fied (Mono Q/Mono S) kinase activator was incubated 
with control or TPA-treated cell extracts. In TPA- 
treated cell extracts there was no increase in the extent 
of ~42 phosphorylation above that induced by TPA 
treatment alone (Fig. 4). By contrast phosphorylation 
of p42 in the control extracts was only observed on 
addition of MAP kinase activator obtained from TPA- 
treated cells; significantly this phosphorylation was on 
both threonine and tyrosine residues (Fig. 4). Compa- 
rison of control extract p42 phosphorylation and MAP 
kinase reactivation showed that these activities co- 
eluted from the h4ono S column (not shown). 
4. DISCUSSION 
TPA pretreatment of intact IJ937 cells stimulates 
phosphorylation of ~42 on tyrosine and threonine resi- 
dues in cell extracts. p42 is identified as MAP kinase on 
the basis of chromatographic properties, co-elution 
with MAP kinase activity and immunological evidence; 
Volume 290, number 1,2 
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phorylation of p42/MAP kinase, when added back. to 
control cell extracts. The MAP kinase activator and 
activated/dephosphorylated MAP kinase has been 
Fraction number 
Fig. 3. Mono Q and Mono S chromatography of MAP kinase activa- 
identified (termed MAP kinase activator). This MAP 
tor. (a) Extracts from control (upper panel) or TPA-treted cells (lower 
kinase activator stimulates threonine and tyrosine phos- 
panel) were chromatographcd on Mono Q (515) columns, washed and 
eluted on a linear gradient (see section 2). MAP kinase activity was 
Act + - - 
assayed in the absence (m) or presence (we) of PPtA-inactivated 
-I= 
TPA + 
phenyl-Sepharose-purified MAP kinasc (1.3 milliunits), (b) Mono Q- 
+- - 
fractionated MAP kinase activator from TPA-treated (lower panel) or 
aeea 
the equivalent fractions from control (upper panel) cells, were re- 
chromatographed on a Mono S (5/§) column (section 2). MAP kinase 
activator was determined by assaying the increase in MAP kinase 
activity on incubation of PPfA-treated MAP kinase (1.3 milliunits) in 
the presence of column fractions. 
the ~42 protein reacts with an antiserum raised to an 
oligopeptide based upon the secp~ence o$ the MAP ki- 
nase homologue EWKl [14] (It is possible that this 
serum would also recognise the related kinase ERK2 
Pm 
A TPA-stimulated activity that reactivates PP2A in- 
p42lMAP kinase phosphorylating activity co-elute on 
Mono S chromatography. 
The results suggest hat a single activity is responsible 
for inducing activation of MAP kinase through phos- 
phorylation on tyrosine and threonine residues. This 
conclusion is entirely consistent with those drawn from 
studies on PC12 sells following NGF treatment (P. 
Cohen personal communication) and also in Swiss 3T3 
cells following EGF treatment [18]. MAP kinase is acti- 
vated by a variety of mitogenic agents [ 19-261 and there 
is evidence for the existence of PKC-dependent and 
independent pathways of activation [27,2&]. 
It remains to be firmly established whether, and if so, 
at what point PKC directly regulates an activity within 
nol. 65, l-l I. 
this kinase cascade. It will be of particular interest if 
[3] Stabel, S, and Parker, P.J. (1991) Pharm. Therap., in press. 
such a defined substrate for PKC can be identified since 
[4] Ashendel, C.L:(1985) Biochim. Biophys. Acta 822, 219-242. 
[5] Kohno, M. (1985) J. Biol. Chem. 260, 1771-1479. 
[6] Rossomando, A.J., Payne, D.M., Weber, M.J. and Sturgill, T.W. 
U937 cells express a number of PKC isoforms (a, j3, 8 
and 4) which could be investigated with respect to their 
(1989) Proc. Natl. Acad. Sci. USA 86, 6940-6943. 
specificity in the regulation of this cascade. 
[7] Ferrell, J.E. and Martin, G.S. (1990) Mol. Cell. Biol. 10, 3020- 
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